Open Positions : Research Scientist, Neurophysiology Arvinas is
a pharmaceutical company focused on developing new small molecules
? known as PROTACs (PROteolysis TArgeting Chimeras) ? aimed at
degrading disease-causing cellular proteins via proteolysis. Based
on innovative research conducted at Yale University by Dr. Craig
Crews, Founder and Chief Scientific Advisor, the company is
translating natural protein degradation approaches into novel drugs
for the treatment of cancer and other diseases. The proprietary
PROTAC-based drug paradigm induces protein degradation, rather than
protein inhibition, using the ubiquitin proteasome system and
offers the advantage of potentially targeting “undruggable” as well
as “druggable” elements of the proteome. This greatly expands the
ability to create drugs for many new, previously unapproachable
targets. For more information, visit www.arvinas.com .
We are seeking a highly motivated senior scientist to join our
efforts in the Neuroscience and Platform Biology Team to contribute
to building our discovery pipeline for neurodegenerative diseases.
This individual will contribute and lead scientific efforts focused
on building a relationship between gene expression correction and
functional physiologic improvement of disease phenotypes in complex
human rodent neuronal models.
This position reports to the Senior Research Investigator,
Neuroscience, and is located at our corporate headquarters in New
Expert in all aspects of neuronal cell biology with a deep
understanding of synaptic physiology and higher throughput
approaches to assess neuronal cell function.
Deep knowledge of molecular, biochemical and pharmacologic
techniques required to examine target expression, modulation and
Demonstrated ability to perform in vitro electrophysiological
recordings in primary rodent or human iPS neurons. Specifically,
experience in the cell culture techniques; electrical recording and
data analysis utilizing multi-electrode arrays is required.
Experience in whole cell patch clamp techniques in either clonal
or primary cultured cells (including neurons) is desired.
Proficiency in development of optical and image-based assay
approaches and software for analysis of electrophysiologic
experiments is desired (i.e., MATLAB). Ability to identify and
solve technical issues that arise with electrophysiology equipment,
especially high throughput electrophysiological recording equipment
Experience and effectiveness working in a multidisciplinary team
drug discovery environment with common goals and operating in a
matrixed environment is essential.
Excellent written and oral communication as demonstrated in the
quality of interactions on projects in a team environment, written
reports and publications focused on network electrophysiology
especially slice and MEA techniques.
Skilled in pharmacologic assessment of both small molecules and
other therapeutic modalities in primary or stem cell derived
Knowledge, application and analysis of compound pharmacology
testing using in vitro disease models.
Able to lead drug discovery programs and collaboratively to
contribute to drug discovery.
Ph.D. in biochemistry, pharmacology, or neuroscience with at
least 5+ years of relevant post-doctoral and / or industry
experience in neurologic and/ or muscle and/ or cardiovascular
monogenic diseases that includes a robust publication record and
experience with in vitro physiology of disease models.
Strong oral and written communication skills and a desire to
work in a team environment are essential.
Manages time effectively and balances work between bench and
Arvinas is proud to offer a competitive package of base and
incentive compensation as well as a comprehensive benefits program
designed to support the health, wellness, and financial security of
our employees and their families. Benefits include group medical,
vision, and dental coverage, group and supplemental life insurance,
and much more. To learn more about Arvinas, please visit
Arvinas is an Equal Opportunity Employer.
Apply for this Position Your Name
Attach Cover Letter
Leading the way in targeted
protein degradation therapeutics.